- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Akti-1/2
別名: Akt Inhibitor VIII
Akti-1/2 (Akt Inhibitor VIII)是高度選擇性的Akt1/Akt2抑制劑，IC50分別為58 nM/210 nM，對Akt1的選擇性比對Akt3高36倍。Akti-1/2 可誘導凋亡。
Akti-1/2 Chemical Structure
CAS: 612847-09-3
產(chǎn)品質(zhì)控
批次：
純度：
99.11%
99.11
Akti-1/2相關產(chǎn)品
相關信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| ME-180 cell | Growth inhibition assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50=3.15011 Μm | SANGER | ||
| NCI-H526 cells | Growth inhibition assay | Inhibition of Akt-mediated antiapoptotic activity in human NCI-H526 cells assessed as disruption of protein-Apaf-1 complex at 50 uM after 24 hrs by Western blot analysis | 17603540 | ||
| MDA-MB-415 cell | Growth inhibition assay | Inhibition of human MDA-MB-415 cell growth in a cell viability assay, IC50=1.73449 μM | SANGER | ||
| MDA-MB-468 cell | Growth inhibition assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50=3.70773 μM | SANGER | ||
| IGROV-1 cell | Growth inhibition assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50=0.72328 Μm | SANGER | ||
| MDA-MB-361 cell | Growth inhibition assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50=0.48995 μM | SANGER | ||
| HCC70 cell | Growth inhibition assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50=0.75078 μM | SANGER | ||
| HGC-27 cell | Growth inhibition assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50=0.15033 μM | SANGER | ||
| ETK-1 | Growth inhibition assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50=4.57383 μM | SANGER | ||
| EFM-19 cell | Growth inhibition assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50=0.56408 μM | SANGER | ||
| EFO-21 cell | Growth inhibition assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50=4.43468 μM | SANGER | ||
| ECC12 cell | Growth inhibition assay | Inhibition of human ECC12 cell growth in a cell viability assay, IC50=8.88569 μM | SANGER | ||
| DSH1 cell | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50=0.98722 μM | SANGER | ||
| DOK cell | Growth inhibition assay | Inhibition of human DOK cell growth in a cell viability assay, IC50=4.15134 μM | SANGER | ||
| DMS-273 cell | Growth inhibition assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=4.15134 μM | SANGER | ||
| Calu-3 cell | Growth inhibition assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50=3.65321 μM | SANGER | ||
| Calu-1 cell | Growth inhibition assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50=7.25613 μM | SANGER | ||
| Ca9-22 cell | Growth inhibition assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50=5.97333 μM | SANGER | ||
| Ca-Ski cell | Growth inhibition assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50=5.3411 μM | SANGER | ||
| CTB-1 cell | Growth inhibition assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=7.59751 μM | SANGER | ||
| COR-L279 cell | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=1.68064 μM | SANGER | ||
| COLO-205 cell | Growth inhibition assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50=1.99706 μM | SANGER | ||
| CHP-212 cell | Growth inhibition assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=4.55867 μM | SANGER | ||
| CESS cell | Growth inhibition assay | Inhibition of human CESS cell growth in a cell viability assay, IC50=2.70089 μM | SANGER | ||
| CCRF-CEM cell | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=4.93541 μM | SANGER | ||
| CCF-STTG1 cell | Growth inhibition assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50=6.81501 μM | SANGER | ||
| YKG-1 cell | Growth inhibition assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50=1.01806 μM | SANGER | ||
| VMRC-RCZ cell | Growth inhibition assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50=3.70955 μM | SANGER | ||
| UACC-893 cell | Growth inhibition assay | Inhibition of human UACC-893 cell growth in a cell viability assay, IC50=5.29339 μM | SANGER | ||
| UACC-62 cell | Growth inhibition assay | Inhibition of human UACC-62 cell growth in a cell viability assay, IC50=27.0545 μM | SANGER | ||
| U251 cell | Growth inhibition assay | Inhibition of human U251 cell growth in a cell viability assay, IC50=19.204 μM | SANGER | ||
| U-698-M cell | Growth inhibition assay | Inhibition of human U-698-M cell growth in a cell viability assay, IC50=39.0015 μM | SANGER | ||
| U-118-MG cell | Growth inhibition assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50=9.90258 μM | SANGER | ||
| TT cell | Growth inhibition assay | Inhibition of human TT cell growth in a cell viability assay, IC50=5.32724 μM | SANGER | ||
| TE-8 cell | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=24.5243 μM | SANGER | ||
| TE-5 cell | Growth inhibition assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50=4.82452 μM | SANGER | ||
| TE-15 cell | Growth inhibition assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50=6.49393 μM | SANGER | ||
| TE-10 cell | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=9.04225 μM | SANGER | ||
| CAL-85-1 cell | Growth inhibition assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50=5.95309 μM | SANGER | ||
| CAL-54 cell | Growth inhibition assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50=4.88625 μM | SANGER | ||
| CAL-51 cell | Growth inhibition assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=7.62841 Μm | SANGER | ||
| CAL-33 cell | Growth inhibition assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50=3.43125 μM | SANGER | ||
| C3A cell | Growth inhibition assay | Inhibition of human C3A cell growth in a cell viability assay, IC50=4.42192 μM | SANGER | ||
| C2BBe1 cell | Growth inhibition assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50=13.6679 μM | SANGER | ||
| C-33-A cell | Growth inhibition assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50=12.4783 μM | SANGER | ||
| BxPC-3 cell | Growth inhibition assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50=2.22442 μM | SANGER | ||
| BB30-HNC cell | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=2.86449 μM | SANGER | ||
| AU565 cell | Growth inhibition assay | Inhibition of human AU565 cell growth in a cell viability assay, IC50=1.23917 μM | SANGER | ||
| AN3-CA cell | Growth inhibition assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50=1.65611 μM | SANGER | ||
| A498 cell | Growth inhibition assay | Inhibition of human A498 cell growth in a cell viability assay, IC50=1.08134 μM | SANGER | ||
| A427 cell | Growth inhibition assay | Inhibition of human A427 cell growth in a cell viability assay, IC50=3.07693 μM | SANGER | ||
| A4-Fuk cell | Growth inhibition assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50=1.8583 μM | SANGER | ||
| 8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=8.63401 μM | SANGER | ||
| 769-P cell | Growth inhibition assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50=1.10483 μM | SANGER | ||
| 697 cell | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=7.17746 μM | SANGER | ||
| 639-V cell | Growth inhibition assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50=5.8773 μM | SANGER | ||
| 23132-87 cell | Growth inhibition assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50=0.75938 μM | SANGER | ||
| 22RV1 cell | Growth inhibition assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50=6.61424 μM | SANGER | ||
| T47D cell | Growth inhibition assay | Inhibition of human T47D cell growth in a cell viability assay, IC50=0.5162 μM | SANGER | ||
| SW954 cell | Growth inhibition assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50=5.85783 μM | SANGER | ||
| SW872 cell | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=14.1435 μM | SANGER | ||
| SW780 cell | Growth inhibition assay | Inhibition of human SW780 cell growth in a cell viability assay, IC50=4.89358 μM | SANGER | ||
| SW1710 cell | Growth inhibition assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50=1.38892 μM | SANGER | ||
| SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=6.81543 μM | SANGER | ||
| SR cell | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=13.0746 μM | SANGER | ||
| SNU-C2B cell | Growth inhibition assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50=22.2673 μM | SANGER | ||
| SNU-C1 cell | Growth inhibition assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50=2.00948 μM | SANGER | ||
| SNU-423 cell | Growth inhibition assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50=5.94933 μM | SANGER | ||
| SNU-387 cell | Growth inhibition assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=4.19544 μM | SANGER | ||
| SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=7.8297 μM | SANGER | ||
| human SN12C cell | Growth inhibition assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50=17.1967 μM | SANGER | ||
| SK-MES-1 cell | Growth inhibition assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50=2.10096 μM | SANGER | ||
| SK-MEL-3 cell | Growth inhibition assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=21.4696 μM | SANGER | ||
| SK-MEL-24 cell | Growth inhibition assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50=13.1675 μM | SANGER | ||
| SK-LU-1 cell | Growth inhibition assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50=42.043 μM | SANGER | ||
| SK-LMS-1 cell | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=8.76452 μM | SANGER | ||
| SK-CO-1 cell | Growth inhibition assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=10.6394 μM | SANGER | ||
| SJSA-1 cell | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=36.9072 μM | SANGER | ||
| SIG-M5 cell | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=12.6604 μM | SANGER | ||
| SF295 cell | Growth inhibition assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50=13.6183 μM | SANGER | ||
| SF268 cell | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=15.1387 μM | SANGER | ||
| SF126 cell | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=10.6746 μM | SANGER | ||
| SCC-9 cell | Growth inhibition assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50=3.08536 μM | SANGER | ||
| SCC-4 cell | Growth inhibition assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50=9.59283 μM | SANGER | ||
| SCC-25 cell | Growth inhibition assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=15.8179 μM | SANGER | ||
| SBC-5 cell | Growth inhibition assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50=20.8325 μM | SANGER | ||
| RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=20.5863 μM | SANGER | ||
| RVH-421 cell | Growth inhibition assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=32.3606 μM | SANGER | ||
| RT-112 cell | Growth inhibition assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50=6.71952 μM | SANGER | ||
| RS4-11 cell | Growth inhibition assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50=6.68645 μM | SANGER | ||
| RPMI-8402 cell | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=16.343 μM | SANGER | ||
| RPMI-2650 cell | Growth inhibition assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50=5.77947 μM | SANGER | ||
| RO82-W-1 cell | Growth inhibition assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=47.2783 μM | SANGER | ||
| RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=19.4439 μM | SANGER | ||
| RERF-LC-MS cell | Growth inhibition assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50=26.1347 μM | SANGER | ||
| REH cell | Growth inhibition assay | Inhibition of human REH cell growth in a cell viability assay, IC50=11.4883 μM | SANGER | ||
| RD cell | Growth inhibition assay | Inhibition of human RD cell growth in a cell viability assay, IC50=20.6036 μM | SANGER | ||
| RCC10RGB cell | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=8.6567 μM | SANGER | ||
| PF-382 cell | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=11.6828 μM | SANGER | ||
| PC-3 cell | Growth inhibition assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.5135 μM | SANGER | ||
| PANC-10-05 cell | Growth inhibition assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50=14.9959 μM | SANGER | ||
| PANC-03-27 cell | Growth inhibition assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50=8.71082 μM | SANGER | ||
| PA-1 cell | Growth inhibition assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50=9.07615 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=4.536 μM | SANGER | ||
| P12-ICHIKAWA cell | Growth inhibition assay | Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=14.7683 μM | SANGER | ||
| OVCAR-4 cell | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=30.466 μM | SANGER | ||
| OVCAR-3 cell | Growth inhibition assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=1.84415 μM | SANGER | ||
| OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=8.52307 μM | SANGER | ||
| OMC-1 cell | Growth inhibition assay | Inhibition of human OMC-1 cell growth in a cell viability assay, IC50=9.25098 μM | SANGER | ||
| OE33 cell | Growth inhibition assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50=1.88926 μM | SANGER | ||
| OE19 cell | Growth inhibition assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50=7.76684 μM | SANGER | ||
| OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=7.72152 μM | SANGER | ||
| OCI-AML2 cell | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=33.2531 μM | SANGER | ||
| OAW-42 cell | Growth inhibition assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=7.31565 μM | SANGER | ||
| NY cell | Growth inhibition assay | Inhibition of human NY cell growth in a cell viability assay, IC50=31.1864 μM | SANGER | ||
| NUGC-3 cell | Growth inhibition assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=16.5906 μM | SANGER | ||
| NOS-1 cell | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=1.36953 μM | SANGER | ||
| NMC-G1 cell | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=42.6693 μM | SANGER | ||
| NKM-1 cell | Growth inhibition assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50=2.75923 μM | SANGER | ||
| NH-12 cell | Growth inhibition assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50=0.60864 μM | SANGER | ||
| NCI-N87 cell | Growth inhibition assay | Inhibition of human NCI-N87 cell growth in a cell viability assay, IC50=29.3042 μM | SANGER | ||
| NCI-H838 cell | Growth inhibition assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50=31.4118 μM | SANGER | ||
| NCI-H747 cell | Growth inhibition assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50=7.62799 μM | SANGER | ||
| NCI-H661 cell | Growth inhibition assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50=5.42326 μM | SANGER | ||
| NCI-H650 cell | Growth inhibition assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50=7.59877 μM | SANGER | ||
| NCI-H64 cell | Growth inhibition assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50=12.5431 μM | SANGER | ||
| NCI-H630 cell | Growth inhibition assay | Inhibition of human NCI-H630 cell growth in a cell viability assay, IC50=5.51055 μM | SANGER | ||
| NCI-H596 | Growth inhibition assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50=17.5708 μM | SANGER | ||
| NCI-H526 cell | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=22.8873μM | SANGER | ||
| NCI-H522 cell | Growth inhibition assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50=11.0874 μM | SANGER | ||
| NCI-H520 cell | Growth inhibition assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50=1.13303 μM | SANGER | ||
| NCI-H460 cell | Growth inhibition assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50=4.62993 μM | SANGER | ||
| NCI-H358 cell | Growth inhibition assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50=19.7233 μM | SANGER | ||
| NCI-H345 cell | Growth inhibition assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50=16.2706 μM | SANGER | ||
| NCI-H292 cell | Growth inhibition assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=6.04837 μM | SANGER | ||
| NCI-H2452 cell | Growth inhibition assay | Inhibition of human NCI-H2452 cell growth in a cell viability assay, IC50=26.6594 μM | SANGER | ||
| NCI-H2405 cell | Growth inhibition assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50=10.4212 μM | SANGER | ||
| NCI-H2347 cell | Growth inhibition assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50=16.1581 μM | SANGER | ||
| NCI-H2342 cell | Growth inhibition assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50=0.93779 μM | SANGER | ||
| NCI-H2228 cell | Growth inhibition assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=2.28604 μM | SANGER | ||
| NCI-H2196 cell | Growth inhibition assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50=24.8003 μM | SANGER | ||
| NCI-H2170 cell | Growth inhibition assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50=18.1028 μM | SANGER | ||
| NCI-H2126 cell | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=12.3371 μM | SANGER | ||
| NCI-H2122 cell | Growth inhibition assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50=10.1385 μM | SANGER | ||
| NCI-H2030 cell | Growth inhibition assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50=1.94483 μM | SANGER | ||
| NCI-H2009 cell | Growth inhibition assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50=7.39019 μM | SANGER | ||
| NCI-H1993 cell | Growth inhibition assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50=22.615 μM | SANGER | ||
| NCI-H1963 cell | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=19.7494 μM | SANGER | ||
| NCI-H1792 cell | Growth inhibition assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50=29.8379 μM | SANGER | ||
| NCI-H1770 cell | Growth inhibition assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50=34.1793 μM | SANGER | ||
| NCI-H1755 cell | Growth inhibition assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50=1.05531 μM | SANGER | ||
| NCI-H1734 cell | Growth inhibition assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50=10.7788 μM | SANGER | ||
| NCI-H1703 cell | Growth inhibition assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=15.577 μM | SANGER | ||
| NCI-H1651 cell | Growth inhibition assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50=16.4338 μM | SANGER | ||
| NCI-H1650 cell | Growth inhibition assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50=11.5134 μM | SANGER | ||
| NCI-H1648 cell | Growth inhibition assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50=5.7551 μM | SANGER | ||
| NCI-H1623 cell | Growth inhibition assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50=15.0596 μM | SANGER | ||
| NCI-H1618 cel | Growth inhibition assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50=21.9982 μM | SANGER | ||
| ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=1.34511 μM | SANGER | ||
| EW-3 cell | Growth inhibition assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50=5.64414 μM | SANGER | ||
| EB2 cell | Growth inhibition assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50=7.75468 μM | SANGER | ||
| DoTc2-4510 cell | Growth inhibition assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50=3.43202 μM | SANGER | ||
| Detroit562 cell | Growth inhibition assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50=4.79465 μM | SANGER | ||
| DV-90 cell | Growth inhibition assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50=6.03122 μM | SANGER | ||
| NCI-H1563 cell | Growth inhibition assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50=0.54246 μM | SANGER | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Akti-1/2 (Akt Inhibitor VIII)是高度選擇性的Akt1/Akt2抑制劑，IC50分別為58 nM/210 nM，對Akt1的選擇性比對Akt3高36倍。Akti-1/2 可誘導凋亡。 | ||||||
|---|---|---|---|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | 在基于細胞的IPKA (C33A)試驗中，Akti-1/2抑制Akt1和Akt2，IC50分別為305 nM和2086 nM。在HT29，MCF7，和A2780細胞中，Akti-1/2通過急劇增加caspase-3活性誘導細胞凋亡。[1] 在肝細胞中，Akti-1/2阻斷胰島素調(diào)節(jié)PEPCK，G6Pase表達，和FOXO1活性。[2] Akti-1/2也會通過阻斷PKB強烈增強PAR-1-介導的血小板聚集。[3] 在HCC827，NCI-H522，NCI-1651，和PC-9細胞中，Akti-1/2抑制細胞生長，IC50 為4.7 μM，7.25 μM，和9.5 μM，結(jié)合時，Akti-1/2會增強細胞生長和凋亡的抑制。[4] |
|||
|---|---|---|---|---|
| 激酶實驗 | 激酶篩選 | |||
| 簡而言之，所有試驗(25.5 μl在21°C下進行30 min)使用Biomek 2000實驗室自動化工作站在96孔格式中進行。反應包含5–20 mU純化的激酶和底物肽或蛋白質(zhì)，通過加入10 mM 乙酸鎂和5，20，或50 μM ATP ([γ-33P]-ATP, 800 cpm/pmol)起始。 | ||||
| 細胞實驗 | 細胞系 | HCC827，NCI-H522，NCI-1651，和 PC-9 細胞 | ||
| 濃度 | ~10 μM | |||
| 孵育時間 | 96小時 | |||
| 方法 | AKTi-1/2的細胞生長抑制作用使用96小時磺酰羅丹明B試驗(SRB)研究。每個化合物抑制50%細胞生長的濃度(IC50)在GraphPad Prism 6.0中使用非線性回歸分析和S形劑量-反應(可變斜率)方程計算。 |
|||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | p-AKT / AKT / p-Foxo3a / p-GSK3β / p-p70S6K / p-S6 / p-4EBP1 / Cyclin D1 / Cyclin D2 / Cyclin D3 / p-Rb / p27 |
|
18725974 | |
| Immunofluorescence | MCM2 / H3K9me2 / CD63 |
|
26637368 | |
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | 在小鼠中，Akti-1/2 (50 mg/kg, i.p.)抑制肺中基底和IGF-刺激的Akt1和 Akt2磷酸化作用。[1] |
|
|---|---|---|
化學信息&溶解度
| 分子量 | 551.64 | 分子式 | C34H29N7O |
| CAS號 | 612847-09-3 | SDF | Download Akti-1/2 SDF |
| Smiles | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=C(N=C6C=C7C(=NC=N7)C=C6N5)C8=CC=CC=C8 | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 22 mg/mL ( (39.88 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解度 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | ||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
Tags: buy Akti-1/2 | Akti-1/2 supplier | purchase Akti-1/2 | Akti-1/2 cost | Akti-1/2 manufacturer | order Akti-1/2 | Akti-1/2 distributor
